On Feb. 13, 2020, the European Medicines Agency (EMA) granted market authorization for Amsparity, Pfizer’s adalimumab biosimilar. Amsparity is approved for use in treating the same set of conditions as Humira in Europe. In 2018, Pfizer announced that it had reached a license agreement with AbbVie that allowed Pfizer to launch its adalimumab biosimilar in Europe upon approval by the EMA. Despite receiving market authorization, Pfizer previously reported in its latest earnings report that it does not plan to launch Amsparity in Europe due to unfavorable market conditions.
The post Biosimilars Update: Amsparity Authorized by EMA but EU Launch Not Expected appeared first on Big Molecule Watch.